{"name":"Chengdu Kanghong Biotech Co., Ltd.","slug":"chengdu-kanghong-biotech-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Intravitreal injection of KH902","genericName":"Intravitreal injection of KH902","slug":"intravitreal-injection-of-kh902","indication":"Wet age-related macular degeneration","status":"phase_2"},{"name":"conbercept, Fixed","genericName":"conbercept, Fixed","slug":"conbercept-fixed","indication":"Diabetic macular edema","status":"phase_3"},{"name":"conbercept, PRN","genericName":"conbercept, PRN","slug":"conbercept-prn","indication":"Neovascular age-related macular degeneration (wet AMD)","status":"phase_3"},{"name":"Conbercept ophthalmic injection","genericName":"Conbercept ophthalmic injection","slug":"conbercept-ophthalmic-injection","indication":"Neovascular age-related macular degeneration (wet AMD)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Placebo + Paclitaxel","genericName":"Placebo + Paclitaxel","slug":"placebo-paclitaxel","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"Intravitreal injection of KH902","genericName":"Intravitreal injection of KH902","slug":"intravitreal-injection-of-kh902","phase":"phase_2","mechanism":"KH902 is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF) signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.","indications":["Wet age-related macular degeneration","Diabetic macular edema","Retinal vein occlusion"],"catalyst":""},{"name":"conbercept, Fixed","genericName":"conbercept, Fixed","slug":"conbercept-fixed","phase":"phase_3","mechanism":"Conbercept is a recombinant human VEGF decoy receptor that inhibits angiogenesis.","indications":["Diabetic macular edema"],"catalyst":""},{"name":"conbercept, PRN","genericName":"conbercept, PRN","slug":"conbercept-prn","phase":"phase_3","mechanism":"Conbercept is a recombinant fusion protein that acts as a soluble decoy receptor to bind and neutralize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF).","indications":["Neovascular age-related macular degeneration (wet AMD)","Diabetic macular edema (DME)","Retinal vein occlusion (RVO)"],"catalyst":""},{"name":"Conbercept ophthalmic injection","genericName":"Conbercept ophthalmic injection","slug":"conbercept-ophthalmic-injection","phase":"phase_3","mechanism":"Conbercept is a recombinant fusion protein that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.","indications":["Neovascular age-related macular degeneration (wet AMD)","Diabetic macular edema (DME)","Retinal vein occlusion (RVO)"],"catalyst":""},{"name":"Placebo + Paclitaxel","genericName":"Placebo + Paclitaxel","slug":"placebo-paclitaxel","phase":"phase_3","mechanism":"Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from growing and dividing.","indications":["Non-small cell lung cancer","Ovarian cancer","Breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxOQnVMZjBIMnRadVZZWkJTZGdNU3E0YkV6blU4ZTZwbEVuV09udVJvZDEzTFRmcjhjb1NhRDctNktxUHA1SmViU0xNYVNZejhOUS1XeFJVR3A2VzQ2MjAweE9EdHJJVzhMV0cxYUM0eF9CV0drVXhwbmQ2bHF2YzE5U2M5V0I5cUhtMXdFM1NjckE1dGhXR21uMzBfeWtaWEtkMkdkZnFZd1NDc3NldFFmVndCUEF3elRtNUJGMUpkLWF0UV9ITHpTOURBVS1KY3ZTN24tMWMzMlEyaGdVUXlLZ2JFRE5wWHhUODVFRGxfQlJTSXVkeTMtclBIbXVSQjJEdGxOSHFYdmxvRmtYUDN5RDdIY1NaRmZhQlpORm1oeXo1alRXbzh6SVUzT25SUlhWN3RXMkJJX1dFS2MyTF8wVjZzVGRqNkU?oc=5","date":"2025-10-23","type":"pipeline","source":"prnewswire.com","summary":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight - prnewswire.com","headline":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Dia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE9wQ0hlMjVZYlZtSGxNM3o4U1BYN0VTbFMzYm5UVFJnZDhMblVNYnZsZzRsUUtNdl9BellRYWdDejhKWXE4MzJQVmR2clV0VDNVdUFQamZVOVVXZmlhT21Dak9QNmt1UWNmSXhNcFY4dHE?oc=5","date":"2025-06-23","type":"pipeline","source":"Rakuten Medical","summary":"Rakuten Medical Strengthens Executive Team with Appointment of CFO Andrew Liu - Rakuten Medical","headline":"Rakuten Medical Strengthens Executive Team with Appointment of CFO Andrew Liu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNZGtWZHFNbTBHS1YyTU1ENWd4Y09VQ3ZPbWQ2NmZyUHlVbl8zdU5JR1hwbl9aN2xQdlNHaWNSdWV4cjlOdEhHMGVSeEtkaWlVOFN5dGRZZHRHLUN4b1dBUmFGNGVIcWhTTi1NTnNnb00yUDlkLXRzTWVtTFZyT1ozbUtGTmxlUnZzZmEwQkZXSEVIXzR1VkxDWlluLVRXR0tDdTZteTQ0V2ZFbGM3TmJjVWM1TEI4MUlHWnRCOEwydmx6YUtreVMybWJoUWxkSkZtb3dYb1VJNjVLSTdFNWotdGY1ZnlxdnNRWkt1Q2VCeGVvbVpfUWptOXlISkhNZ01FQWF3Zks5YWVJQ0FVYkVpV2x1TnVTdVpK?oc=5","date":"2025-06-09","type":"regulatory","source":"prnewswire.com","summary":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight - prnewswire.com","headline":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOSTBTR2Uta25lV3JDN09ySjVNQlgtSG94Z1hkclBXcmc3cm9RcDRxN1dnSHZxYnNXUzdydTU2aEhsWk1UaTdkRVpPRS1iV080T3pRSGxNcXMyV2dhRHBfdUt4dm5WOUVVSmI2Uml2UWljd3VTT0UtVmROc2pGWTRDblVDQ2dZYUljNkhsb1Z4ZzB5OWlXNGR6QnBkUF9FOFc3M3BBSjdGanpFSDRUa1dVcUpGY3BTQlhqUVlSQklnRHNZZ0FPd0VjaGlSc21uYlVlVlZpbnJxM2U?oc=5","date":"2025-05-07","type":"pipeline","source":"UMass Chan Medical School","summary":"Origen Biotechnology funds research at UMass Chan to advance gene therapy technology - UMass Chan Medical School","headline":"Origen Biotechnology funds research at UMass Chan to advance gene therapy technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPZnNiRk9QWjh0NlAzNkVOSFZvaENDbjlRVGxoUGUtU3BIM3FuRkNIUGo5WGlhLWFVcTRRd3h0NlFqc3pkUmZLbG1xRE5aZFcxaWFVbTA1SWFsZUhCYnVjREw0MUItS0JEWjF0bXZWSi1TbFltd01xb09kMkdSV2V3Ty12QlZibVdjUmQtVTBPMEdTc0t2Vlptc0F3X2wyblppNzhSSnZod2F3UmJiRGxYN0tSOWpQM3M3WXB0dUs0c1JQQ0k2V2VYbVZRYVh2MlZ5ZUFHTm1R?oc=5","date":"2024-09-27","type":"pipeline","source":"prnewswire.com","summary":"AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR | MarketsandMarkets™ - prnewswire.com","headline":"AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR | MarketsandMarkets™","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBQRXFjcWZiX2VUV0ZNNmpSbFRmaFRxamVQemFTUE9xVHdUYzZPOXFiNHJhdkxDNU5KeFBZVWs0RzZrbTBNekFHVG56NmExVWpGMTB4MFVma3ByWFpyVFRV?oc=5","date":"2024-05-06","type":"pipeline","source":"Nature","summary":"An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species - Nature","headline":"An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZUdiMUI2RERBcXVHOGg4c1g3Y0Z2QzhwcTF4NTBaazBsOEE0MXdPTl93NEctQkE4Q1QzQTV4RFBrU0RhVXFmeUZnV3ZUT3l3Nmc3MzFraVRDT2Fvdkp3M3cxXy0yUmFhd3NnWm5uZ2pSZ3BqampMcGh0czl2ZWNFemJJYkZTcXdpd01PcS10NW1GSTBiYm5wMWhxc2xLTUlTSGkwT09lQVB4aFJvT0JfdVgzdXRnWnd6bnR3?oc=5","date":"2013-05-13","type":"regulatory","source":"Asian Scientist Magazine","summary":"Sagent Pharma To Acquire Remaining Interest In Chengdu Kanghong Pharma - Asian Scientist Magazine","headline":"Sagent Pharma To Acquire Remaining Interest In Chengdu Kanghong Pharma","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":1,"phase_3":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}